Adamas Pharmaceuticals Inc (ADMS) was among the biggest gainers on the Russell 2000 for Wednesday December 23 as the stock popped 63.46% to $27.56, representing a gain of $10.7 per share. Some 5.81 million shares traded hands on 31,457 trades, compared with an average daily volume of 120,014 shares out of a total float of 18.42 million. The stock opened at $22.76 and traded with an intraday range of $27.70 to $22.50.
After today's gains, Adamas Pharmaceuticals Inc reached a market cap of $507.71 million. Adamas Pharmaceuticals Inc has had a trading range between $30.86 and $12.73 over the last year, and it had a 50-day SMA of $15.49 and a 200-day SMA of $19.22.
Adamas Pharmaceuticals Inc is a specialty pharmaceutical company, is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. Its portfolio includes Namzaric and Namenda XR.
Adamas Pharmaceuticals Inc is based out of Emeryville, CA and has some 59 employees. Its CEO is Gregory Went.
For a complete fundamental analysis analysis of Adamas Pharmaceuticals Inc, check out Equities.com’s Stock Valuation Analysis report for ADMS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer